Vascular sympathetic and nitrergic neuronal pathways

The vascular sympathetic and nitrergic neuronal pathways represent a dualistic neurogenic system responsible for the fine-tuning of vascular resistance and blood flow (Toda & Okamura, 2003, Pharmacological Reviews). The sympathetic component primarily utilizes norepinephrine to activate alpha-1 and alpha-2 adrenergic receptors, leading to vasoconstriction and increased peripheral resistance (StatPearls, Physiology, Adrenergic Receptors). In contrast, the nitrergic component releases nitric oxide (NO) synthesized by neuronal nitric oxide synthase (nNOS) to induce vasodilation via the activation of soluble guanylate cyclase (UniProt P29475). This balance is essential for the physiological regulation of specific vascular beds, including the cerebral, mesenteric, and penile circulations (PubMed, PMID: 12679555). Dysregulation of these pathways, such as impaired nitrergic signaling or sympathetic overactivity, is a hallmark of cardiovascular diseases like hypertension and vasospastic disorders (NIH, National Heart, Lung, and Blood Institute). Therapeutic strategies often target individual components of these pathways, such as using phosphodiesterase-5 (PDE5) inhibitors like sildenafil to enhance nitrergic-mediated vasodilation (PubChem, CID 5212). Because this entry describes a functional interaction between two distinct neuronal systems rather than a single molecule, it is categorized as a physiological pathway rather than a discrete molecular target.

Other names

Neurogenic vascular controlAdrenergic-nitrergic balancePerivascular autonomic nervous systemSympathetic-nitrergic interaction

Pharmacological agents modulate these pathways by either antagonizing sympathetic vasoconstriction (e.g., alpha-adrenergic blockers) or enhancing nitrergic vasodilation (e.g., PDE5 inhibitors or nitric oxide donors).